Amended Statement of Ownership (sc 13g/a)
February 16 2021 - 8:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Amendment No. 1)*
Gamida Cell Ltd.
(Name of Issuer)
Ordinary Share, NIS 0.01 par value
(Title of Class of Securities)
M47364100
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act
of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
CUSIP No. M47364100
|
13G
|
Page 2 of 9 Pages
|
1
|
NAME OF REPORTING PERSONS
Elbit Cord Blood Ltd. Partnership
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See
instructions)
(a) ☐
(b) ☒
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Israel
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5
|
SOLE VOTING POWER
---
|
6
|
SHARED VOTING POWER
1,828,373 (*)
|
7
|
SOLE DISPOSITIVE POWER
---
|
8
|
SHARED DISPOSITIVE POWER
1,828,373 (*)
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,828,373 (*)
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (See instructions)
☐
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
3.1% (*) (**)
|
12
|
TYPE OF REPORTING PERSON (See instructions)
IN
|
|
(*)
|
The beneficial ownership of the securities reported herein
is described in Item 4(a).
|
|
(**)
|
All percentages of ownership of the Ordinary Shares by
Reporting Persons presented in this Statement assume an aggregate of 59,000,153 ordinary shares issued and outstanding as of December
31, 2020, as provided by the Issuer.
|
CUSIP No. M47364100
|
13G
|
Page 3 of 9 Pages
|
1
|
NAME OF REPORTING PERSONS
Elbit Medical Technologies Ltd.
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See
instructions)
(a) ☐
(b) ☒
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Israel
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5
|
SOLE VOTING POWER
---
|
6
|
SHARED VOTING POWER
1,828,373 (*)
|
7
|
SOLE DISPOSITIVE POWER
---
|
8
|
SHARED DISPOSITIVE POWER
1,828,373 (*)
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,828,373 (*)
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (See instructions)
☐
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
3.1% (*) (**)
|
12
|
TYPE OF REPORTING PERSON (See instructions)
CO
|
|
(*)
|
The beneficial ownership of the securities reported herein
is described in Item 4(a).
|
|
(**)
|
All percentages of ownership of the Ordinary Shares by
Reporting Persons presented in this Statement assume an aggregate of 59,000,153 ordinary shares issued and outstanding as of December
31, 2020, as provided by the Issuer.
|
CUSIP No. M47364100
|
13G
|
Page 4 of 9 Pages
|
1
|
NAME OF REPORTING PERSONS
Elbit Imaging Ltd.
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See
instructions)
(a) ☐
(b) ☒
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Israel
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5
|
SOLE VOTING POWER
---
|
6
|
SHARED VOTING POWER
1,828,373 (*)
|
7
|
SOLE DISPOSITIVE POWER
---
|
8
|
SHARED DISPOSITIVE POWER
1,828,373 (*)
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,828,373 (*)
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (See instructions)
☐
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
3.1% (*) (**)
|
12
|
TYPE OF REPORTING PERSON (See instructions)
CO
|
|
(*)
|
The beneficial ownership of the securities reported herein
is described in Item 4(a).
|
|
(**)
|
All percentages of ownership of the Ordinary Shares by
Reporting Persons presented in this Statement assume an aggregate of 59,000,153 ordinary shares issued and outstanding as of December
31, 2020, as provided by the Issuer.
|
CUSIP No. M47364100
|
13G
|
Page 5 of 9 Pages
|
Item 1. (a)
|
Name of Issuer:
|
Gamida Cell Ltd.
|
(b)
|
Address of Issuer’s Principal Executive Offices:
|
5
Nahum Heftsadie Street, Givaat Shaul, Jerusalem 91340 Israel
Item 2. (a)
|
Name of Person Filing:
|
Elbit Cord Blood Ltd. Partnership
Elbit Medical Technologies Ltd.
Elbit Imaging Ltd.
|
(b)
|
Address of Principal Business Office:
|
Elbit Cord Blood Ltd. Partnership – 3 Shimshon
Street, Petach Tikva, Israel
Elbit Medical Technologies Ltd. – 3 Shimshon
Street, Petach Tikva, Israel
Elbit Imaging Ltd. – 3 Shimshon Street, Petach
Tikva, Israel
Elbit Cord Blood Ltd. Partnership – Israel
Elbit Medical Technologies Ltd. – Israel
Elbit Imaging Ltd. – Israel
|
(d)
|
Title of Class of Securities:
|
Ordinary Share, NIS0.01 par value
M47364100
CUSIP No. M47364100
|
13G
|
Page 6 of 9 Pages
|
|
(a)
|
Amount beneficially owned:
|
See row
9 of cover page of each reporting person.
The securities reported herein are held directly by
Elbit Cord Blood Ltd. Partnership (“ECB”), an Israeli limited partnership. Elbit Medical Technologies Ltd. (“EMT”)
is the general partner of ECB and holds 99.9% of the partnership interests of ECB. Elbit Imaging Ltd. (“EI”) is
an Israeli public company listed on the Tel-Aviv Stock Exchange. EI holds approximately 15.4% of the issued and outstanding shares
of EMT.
This Statement shall not be construed as an admission
by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting
Person disclaims beneficial ownership of any such securities. In addition, the Reporting Persons and other entities named in this
Schedule 13G may be deemed to constitute a “group” for purposes of Section 13(d) of the Securities Exchange Act of 1934.
Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists
for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the Reporting Persons
and other entities named in this Schedule 13G disclaims the existence of any such group.
See row 11 of cover page of each
reporting person
|
(c)
|
Number of shares as to which such person has:
|
|
(i)
|
Sole power to vote or to direct the vote:
|
See row 5 of cover page of each reporting
person
|
(ii)
|
Shared power to vote or to direct the vote:
|
See row 6 of cover page of each reporting person
and note in Item 4(a) above
|
(iii)
|
Sole power to dispose or to direct the disposition of:
|
See row 7 of cover page of each reporting
person
|
(iv)
|
Shared power to dispose or to direct the disposition of:
|
See row 8 of cover page of each reporting person
and note in Item 4(a) above
CUSIP No. M47364100
|
13G
|
Page 7 of 9 Pages
|
Item 5.
|
Ownership of Five Percent or Less of a Class:
|
If this statement is being filed to report the fact
that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities,
check the following ☒.
Item 6.
|
Ownership of More than Five Percent on Behalf of Another:
|
Not applicable.
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
|
Not applicable.
Item 8.
|
Identification and Classification of Members of the Group:
|
|
|
|
Not applicable.
|
|
|
Item 9.
|
Notice of Dissolution of Group:
|
|
|
|
Not applicable.
|
|
|
Item 10.
|
Certification:
|
|
|
|
Not applicable.
|
CUSIP No. M47364100
|
13G
|
Page 8 of 9 Pages
|
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
February 15, 2021
|
Elbit Cord Blood Ltd. Partnership
|
|
|
|
/s/ Yael Naftali, Tsipi Siani Amossi
|
|
By: Yael Naftali, Tsipi Siani Amossi
|
|
Title: Authorized Signatories
|
|
|
|
Elbit Medical Technologies Ltd.
|
|
|
|
/s/ Yael Naftali, Tsipi Siani Amossi
|
|
By: Yael Naftali, Tsipi Siani Amossi
|
|
Title: Authorized Signatories
|
|
|
|
Elbit Imaging Ltd.
|
|
|
|
/s/ Yael Naftali, Tsipi Siani Amossi
|
|
By: Yael Naftali, Tsipi Siani Amossi
|
|
Title: Authorized Signatories
|
CUSIP No. M47364100
|
13G
|
Page 9 of 9 Pages
|
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Sep 2023 to Sep 2024